000			04154cam a2200421M 4500
999			_c9650 _d9650
001			9650
003			ES-VaUE
005			20210514142827.0
006			m o d
007			cr |n|||||||||
008			201024s2020 xx o 0|| 0 eng d
017			_a1204134714
020			_a9783030573171 ( _q) ( _qelectronic bk.)
020			_a3030573176 ( _q) ( _qelectronic bk.)
020			_z3030573168
020			_z9783030573164
024	1		_aAU@ _b000068176389
040			_aYDX _beng _cYDX _dEBLCP _dUKAHL
050			_aRB633 _b.C67 2021 EB
245	0	0	_aInfection Management in Hematology _cOliver A. Cornely, Martin Hoenigl
250			_a1st ed. 2021
260			_aCham _bSpringer _c2021
300			_a1 online resource
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
490	1		_aHematologic Malignancies Ser
505	0		_aIntro -- Preface -- Contents -- 1: Epidemiology and Risk Factors of Invasive Fungal Infections -- 1.1 Introduction -- 1.2 Hematopoietic Stem Cell Transplantation (HSCT) -- 1.3 Acute Leukemia -- 1.4 Other Hematologic Diseases -- 1.5 Invasive Candidiasis -- 1.6 Other Invasive Yeast Infections -- 1.7 Invasive Aspergillosis -- 1.8 Mucormycosis -- 1.9 Fusariosis -- 1.10 Other Invasive Mold Infections -- 1.11 Pneumocystosis -- 1.12 Endemic Mycoses -- 1.13 Risk Stratification and Preventive Strategies -- References -- 2: Antibacterial and Antiparasitic Prophylaxis -- 2.1 Introduction
505	8		_a2.2 Antibacterial Prophylaxis -- 2.2.1 Who Is at Risk? -- 2.2.2 Antibacterial Prevention Strategies in Neutropenic Patients: Past and Present -- 2.3 Concerns About Antibiotic Prophylaxis -- 2.3.1 Treatment Cost -- 2.3.2 Antibiotic Resistance -- 2.4 Antiparasitic Prophylaxis -- 2.4.1 Introduction -- 2.4.2 Recommendations for Prevention of Specific Infections -- 2.4.2.1 Enteric Pathogens -- 2.4.2.2 Infections Transmitted by Arthropod Bites -- 2.4.2.3 Infections Transmitted Through Skin and Mucous Membranes -- References -- 3: Antifungal Prophylaxis -- 3.1 Introduction
505	8		_a3.2 General Measures for Prevention of Invasive Fungal Infections -- 3.3 Acute Myeloid Leukaemia and Myelodysplastic Syndromes -- 3.4 Allogeneic Haematopoietic Stem Cell Transplantation -- 3.5 Autologous Haematopoietic Stem Cell Transplantation -- 3.6 Novel Therapeutic Agents and Fungal Risk in Other Haematological Malignancies -- 3.7 Aplastic Anaemia -- 3.8 Secondary Prophylaxis -- 3.9 Primary Prophylaxis as Part of the Antifungal Management Continuum -- References -- 4: Antiviral Prophylaxis -- 4.1 Herpes Viruses -- 4.1.1 Herpes Simplex Virus (HSV)
505	8		_a4.1.2 Varicella-Zoster Virus (VZV) -- 4.1.3 Cytomegalovirus (CMV) -- 4.2 Respiratory Viruses -- 4.3 Hepatotropic Viruses -- 4.4 Polyomaviruses -- 4.5 Other Viruses -- References -- 5: Immune Response to Vaccines -- 5.1 Introduction -- 5.2 Vaccine Immune Response -- 5.2.1 Live Vaccines -- 5.2.2 Non-Live Vaccines -- 5.2.3 Vaccine Adjuvants -- 5.2.4 Stages of Immunization -- 5.2.4.1 The Extrafollicular Vaccine Immune Reaction -- 5.2.4.2 The Germinal Centre Vaccine Immune Reaction -- 5.3 Determining Factors of Vaccine Immune Response -- 5.3.1 Host Factors -- 5.3.1.1 Age
505	8		_a5.3.1.2 Genetic Factors -- 5.3.2 Nature of the Vaccine -- 5.3.3 Schedule of Vaccination -- 5.4 Specificity of Vaccine Immune Response -- References -- 6: Vaccine-Preventable Diseases -- 6.1 Influenza -- 6.1.1 Hematological Malignancies and Influenza -- 6.1.2 Hematopoietic Stem Cell Transplantation (HSCT) and Influenza -- 6.1.2.1 Timing of the Vaccination -- 6.1.2.2 Vaccination of the Household -- 6.1.2.3 Vaccination of the Donor -- 6.2 Fungal Infections and Vaccination -- 6.3 Herpes Zoster -- 6.3.1 Hematological Malignancies and Herpes Zoster
655		0	_aElectronic books
776	0	8	_cOriginal _z3030573168 _z9783030573164 _w(OCoLC)1176316183
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-57317-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db